Wechselwirkungen · Fycompa
Fycompa 0.5 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 30
HOS-125903 · Präparat HOS-096179
Based on the results from the population pharmacokinetic analysis of patients with partial-onset seizures and patients with primary generalised tonic-clonic seizures the total clearance of Fycompa was increased when co-administered with carbamazepine (3-fold), and phenytoin or oxcarbazepine (2-fold), which are known inducers of enzymes of metabolism (see section 5.2). This effect should be taken into account and managed when adding or withdrawing these anti-epileptic drugs from a patient’s treatment regimen. Clonazepam, levetiracetam, phenobarbital, topiramate, zonisamide, clobazam, lamotrigine and valproic acid did not affect to a clinically relevant manner the clearance of Fycompa.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) zonisamide (HOS-113349) topiramate (HOS-110310) phenobarbital (HOS-085617) valproic acid (HOS-088515) carbamazepine (HOS-085618) clonazepam (HOS-116372) clobazam (HOS-115305) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) levetiracetam (HOS-090742)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-26T10:26:00Z · SHA-256 b5542bbc20a489b9730fd4bf2ab7b210c2adb03b3f707d2db6edd804a3f94228 · Passage 0082e100157a5b8d067c8c128173d1d009cc83c573888e5b8dcb2b89cb2beac5 · Zeichen 2736–3428 im Abschnitt